From Bettina Bauer, Vice President, US HIV Treatment and Prevention, Gilead Sciences In 2022, there were up to 1.2 million ...
Data from a phase Ia clinical trial of an oral, long-acting integrase inhibitor (GS-1720) in development for HIV demonstrated ...
When the Centers for Disease Control and Prevention published data in May that showed overall progress in reducing new HIV infections, everyone breathed a sigh of relief — and had the sense that the ...
A sign for free HIV testing sits in front of JASMYN’s clinic and administration building in Jacksonville. Bob Self/Florida ...
Experts said they hope to finally get legislation across the finish line to improve how students are taught about HIV and to ...
A new report shows most of the conduct targeted by Indianas HIV criminalization laws carry no risk of transmission. Advocates ...
Timely care and support help HIV patients reach a zero-transmission goal. Harris Health's READI program shows how to manage ...
The combination therapy of bictegravir/emtricitabine/tenofovir (BIC/FTC/TAF) was both tolerable and produced virologic ...
Gilead (GILD) reported positive results from a pivotal Phase 3 study of its twice-yearly HIV prevention treatment lenacapavir ...
People on MSN12d
Man Born with HIV Shares How He and His Wife Are Expecting an HIV-Negative Baby: 'I Was Able to Break a Cycle' (Exclusive)Joseph Kibler and his wife, Carey Cox, shared that they're expecting a baby who will be HIV-negative, despite Kibler's ...
People with HIV are living longer because of treatment advances. This also means they may be living with several other health conditions, such as heart disease, type 2 diabetes, and more.
Specific subtypes and transmission clusters for HIV could require targeted interventions to control spread of HIV that is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback